egnite, and JenaValve Announce Strategic Partnership to Uncover Trends in Care for Patients with Aortic Regurgitation

By Business Wire On Jun 12, 2023

– Partnership aims to understand the care paradigm and associated outcomes for patients with aortic regurgitation –

– First study presented by Nick Amoroso, MD, at the TVT Structural Heart Summit in Phoenix, Arizona –

egnite, a leading digital health company for cardiovascular care, and JenaValve Technology, a developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, are pleased to announce a strategic partnership aimed to shed light on the care paradigm and associated outcomes of patients with aortic regurgitation (AR). The partnership leverages egnite’s industry-leading database to quantify prevalence and treatment patterns and has conservatively estimated there may be over 500,000 patients in the United State11s diagnosed with moderate or severe AR.

“This is one of the first artificial intelligence-driven studies providing critical insights into care patterns for patients with moderate or greater AR in the community”

Duane Pinto, MD, CMO of JenaValve, further emphasized the need for broader access to therapies, stating, “By utilizing cutting-edge analytics and JenaValve’s innovative transcatheter therapies, we hope to drive urgent change, provide improved treatment options, and ultimately save lives. These findings also provide valuable insights for healthcare providers and policymakers, encouraging further attention toward improving outcomes for patients suffering from AR.”

Interventional cardiologist Dr. Nicholas S. Amoroso presented the first study from this partnership at TVT: The Structural Heart Summit. This novel study examined two-year treatment rates and outcomes for patients with AR utilizing over 1 million patients from 25 leading teaching and non-teaching cardiovascular programs across the United States from egnite’s database.

Key findings uncovered that despite high two-year mortality rates and guideline indications for treatment, patients with severe AR received low rates of specialist evaluations and treatment with aortic valve replacement. The study also demonstrated that patients diagnosed with moderate or severe AR and severe left ventricular dilation exhibited similar mortality rates, suggesting that some patients may benefit from earlier assessment by the Heart Team.

“This is one of the first artificial intelligence-driven studies providing critical insights into care patterns for patients with moderate or greater AR in the community,” stated Nicholas S. Amoroso, Assistant Professor at the Medical University of South Carolina. “The urgency for digital technologies to identify AR patients earlier and novel therapies to improve outcomes for this vulnerable patient population has never been greater.”

[To share your insights with us, please write to sghosh@martechseries.com]